Dr. Reckamp on Pivotal Data in METex14-Altered NSCLC

July 26, 2019
Karen Reckamp, MD, MS

Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non–small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non—small cell lung cancer (NSCLC).

In the VISION study, tepotinib demonstrated a median progression-free survival (PFS) of 9 to 12 months in this patient population, according to Reckamp, adding that this is very comparable with frontline chemotherapy plus immunotherapy or immunotherapy alone in patients with high PD-L1 expression. Reckamp believes tepotinib looks to be a potential first-line treatment for patients with MET exon 14-altered advanced NSCLC.

In the GEOMETRY study, capmatinib showed a 68% response rate in the frontline setting and a median PFS of 9.6 months, according to Reckamp. In these patients, there was a 50% response rate in the brain for patients who had measurable disease in the brain.


x